Share price blitzed, analysts in an uproar after lead PhIII drug implodes — and Biogen unveils a $2.5M raise for the CEO
At this stage, you have to give Biogen CEO Michel Vounatsos top marks for the worst timing in the industry.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
